Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jarrow Formulas' Vinpocetine Claim Cited In FDA "Courtesy" Letter

This article was originally published in The Tan Sheet

Executive Summary

Jarrow Formulas' Vinpocetine 5 mg is cited by FDA in a Sept. 8 "courtesy" letter for making a structure/ function claim referring to "brain metabolism."

You may also be interested in...

Nature Made Vinpocetine Promoted For Enhanced Mental Acuity

Pharmavite's Nature Made line of nutritional supplements is expanding to include the first mass market product in the U.S. that contains vinpocetine as a stand-alone ingredient. A derivative of the periwinkle plant, the botanical is promoted as helping "improve memory and concentration."

GNC Vincamine Supplement Cleared For Short-Term Adult Use

A dietary supplement providing up to 20 mg of vincamine per day is reasonably expected to be safe when consumed by healthy adults for up to six months, FDA says in a letter to GNC recently made available by the agency.

GNC Vincamine New Dietary Ingredient Safety Notice To Be Resubmitted

General Nutrition Corporation plans to resubmit its new dietary ingredient premarket notification to FDA for a derivative of vinca minor (periwinkle) called vincamine.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts